See more : Nass Valley Gateway Ltd. (NSVGF) Income Statement Analysis – Financial Results
Complete financial analysis of Scilex Holding Company (SCLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scilex Holding Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Sarissa Capital Acquisition Corp. (SRSAU) Income Statement Analysis – Financial Results
- Singapore Post Limited (S08.SI) Income Statement Analysis – Financial Results
- Creative Edge Nutrition, Inc. (FITX) Income Statement Analysis – Financial Results
- Allcargo Logistics Limited (ALLCARGO.BO) Income Statement Analysis – Financial Results
- Straightup Resources Inc. (STUPF) Income Statement Analysis – Financial Results
Scilex Holding Company (SCLX)
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 46.74M | 38.03M | 31.32M | 23.56M | 21.03M |
| Cost of Revenue | 15.68M | 10.80M | 3.63M | 2.15M | 5.80M |
| Gross Profit | 31.06M | 27.24M | 27.68M | 21.41M | 15.23M |
| Gross Profit Ratio | 66.45% | 71.61% | 88.40% | 90.88% | 72.41% |
| Research & Development | 12.75M | 9.05M | 9.20M | 9.96M | 85.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 119.64M | 64.90M | 50.58M | 42.97M | 64.70M |
| Other Expenses | 4.11M | 3.92M | 3.74M | 3.74M | 3.71M |
| Operating Expenses | 136.49M | 77.87M | 63.52M | 56.67M | 153.93M |
| Cost & Expenses | 152.17M | 88.67M | 67.16M | 58.82M | 159.73M |
| Interest Income | 0.00 | 9.60M | 11.76M | 13.12M | 460.00K |
| Interest Expense | 1.07M | 9.60M | 39.76M | 13.12M | 16.89M |
| Depreciation & Amortization | 4.15M | 4.45M | 4.15M | 3.78M | 3.75M |
| EBITDA | -109.10M | -9.30M | -44.88M | -31.48M | -134.49M |
| EBITDA Ratio | -233.41% | -122.71% | -102.37% | -133.62% | -639.40% |
| Operating Income | -105.43M | -50.63M | -35.84M | -35.26M | -138.70M |
| Operating Income Ratio | -225.55% | -133.13% | -114.44% | -149.65% | -659.42% |
| Total Other Income/Expenses | -8.89M | 27.27M | -52.58M | -12.31M | -39.90M |
| Income Before Tax | -114.32M | -23.36M | -88.42M | -47.57M | -178.59M |
| Income Before Tax Ratio | -244.57% | -61.42% | -282.34% | -201.92% | -849.10% |
| Income Tax Expense | 13.00K | 4.00K | 5.00K | -53.00K | 2.00K |
| Net Income | -114.33M | -23.36M | -88.42M | -47.52M | -178.59M |
| Net Income Ratio | -244.59% | -61.43% | -282.35% | -201.69% | -849.11% |
| EPS | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| EPS Diluted | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| Weighted Avg Shares Out | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
| Weighted Avg Shares Out (Dil) | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
Scilex Holding Company Announces $15 Million Registered Direct Offering
PALO ALTO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
PALO ALTO, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
PALO ALTO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that...
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that...
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
PALO ALTO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Source: https://incomestatements.info
Category: Stock Reports